California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
HEIDELBERG, Germany, Nov. 08, 2016 -- Affimed N.V. (Nasdaq:AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced that three of the Company’s abstracts have been chosen for poster presentations at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 3-6, 2016 in San Diego, California.
Poster Information
| AFM13 Is the Most Advanced Bispecific NK-Cell Engaging Antibody in Clinical Development Substantially Enhancing NK-Cell Effector Function and Proliferation (Abstract #1764) |
| Session: 622. Lymphoma Biology - Non-Genetic Studies: Poster I |
| Date: Saturday, December 3, 2016: 5:30-7:30 p.m. (PT) |
| Location: Hall GH (San Diego Convention Center) |
| Functional Defects of T Cells of NHL Patients after Different Chemotherapy Regimens Activated By CD19/CD3 Tetravalent Bispecific TandAb® AFM11 (Abstract #4130) |
| Session: 622. Lymphoma Biology - Non-Genetic Studies: Poster III |
| Date: Monday, December 5, 2016: 6:00-8:00 p.m. Pacific Time |
| Location: Hall GH (San Diego Convention Center) |
| Trispecific Antibodies for Selective CD16A-Directed NK-Cell Engagement in Multiple Myeloma (Abstract #4513) |
| Session: 653. Myeloma: Therapy, excluding Transplantation: Poster III |
| Date: Monday, December 5, 2016: 6:00-8:00 p.m. Pacific Time |
| Location: Hall GH (San Diego Convention Center) |
About AFM13
AFM13 is a bispecific NK-cell TandAb simultaneously targeting CD16A on NK-cells and CD30 on tumor cells. AFM13 is designed to treat CD30-positive malignancies including Hodgkin lymphoma (HL) and T-cell lymphoma (TCL) and is currently in Phase 2 studies in HL patients. Based on its appropriate safety profile, AFM13 is being developed both as monotherapy and in combination with other therapeutics such as our collaboration partner Merck’s checkpoint inhibitor KEYTRUDA®.
About AFM11
AFM11 is a bispecific T-cell TandAb simultaneously targeting CD3 on T-cells and CD19 on tumor cells. AFM11 is specifically designed to treat B-cell malignancies including non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL), in which CD19 is expressed at abnormally high levels. AFM11 is currently in Phase 1 clinical development for NHL and ALL.
About NK- and T-Cell TandAbs and Trispecific Antibodies
TandAbs and Trispecific Abs are immune cell-engaging antibodies with a tetravalent architecture characterized by four binding domains. Affimed develops products from three proprietary platforms:
- Bispecific TandAbs engaging NK-cells (via CD16A)
- Bispecific TandAbs engaging T-cells (via CD3)
- Trispecific Abs engaging either NK- or T-cells
Affimed develops TandAbs and Trispecific Abs to substantially increase the efficacy, specificity and/or extend the therapeutic window of current therapeutics. Binding to targets on both the immune and the tumor cell, they redirect immune cells and establish a bridge between either NK-cells or T-cells and cancer cells, triggering a signal cascade that leads to the destruction of cancer cells. In clinical studies, our TandAb products have already demonstrated promising signs of therapeutic activity in patients.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
IR Contact:
Caroline Stewart, Head IR
Phone: +1 347394 6793
E-Mail: [email protected] or [email protected]
Media Contact:
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: [email protected]
